POAI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
POAI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Predictive Oncology's accounts receivables for the quarter that ended in Dec. 2023 was $0.33 Mil.
Accounts receivable can be measured by Days Sales Outstanding. Predictive Oncology's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 90.98.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Predictive Oncology's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $0.76.
The historical data trend for Predictive Oncology's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Predictive Oncology Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Accounts Receivable | Get a 7-Day Free Trial | 0.30 | 0.26 | 0.35 | 0.33 | 0.33 |
Predictive Oncology Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Accounts Receivable | Get a 7-Day Free Trial | 0.33 | 0.28 | 0.43 | 0.55 | 0.33 |
Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Predictive Oncology's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0.334 | / | 0.335 | * | 91 |
= | 90.98 |
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Predictive Oncology's accounts receivable are only considered to be worth 75% of book value:
Predictive Oncology's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:
Net-Net Working Capital Per Share | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (8.729 | + | 0.75 * 0.334 | + | 0.5 * 0.494 | - | 6.145 |
- | 0.001 | - | 0) | / | 4.06285 | ||
= | 0.76 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Thank you for viewing the detailed overview of Predictive Oncology's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert L Myers | officer: CHIEF FINANCIAL OFFICER | 4765 BEACON HILL ROAD, EAGAN MN 55122 |
Nuzum Charles Lee Sr | director | 633 1ST STREET WEST, SONOMA CA 95476 |
Veena Rao | director | 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121 |
Matthew Hawryluk | director | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
St. Clair Gregory Sr | director | 1645 WHITLEY DRIVE, HARRISBURG PA 17111 |
Nancy Chung-welch | director | P O BOX 1572, PEPPERELL MA 01463 |
Pamela Bush | officer: Chief Business Officer | 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121 |
Daniel E Handley | director | 1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765 |
Raymond F Vennare | director | 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121 |
David Stewart Smith | director | 151 WASHINGTON STREET, PITTSBURGH PA 15218 |
J Melville Engle | director | 1 REMINGTON COURT, NAPA CA 94558 |
Jenkins Christina Lee Md | director | 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121 |
Carl I. Schwartz | 10 percent owner | 20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180 |
Richard L Gabriel | director | 900 COCOANUT AVENUE, SARASOTA FL 34236 |
Pamela S Prior | director | 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121 |
From GuruFocus
By GlobeNewswire • 08-10-2023
By Value_Insider Value_Insider • 12-13-2022
By sperokesalga sperokesalga • 04-20-2023
By sperokesalga sperokesalga • 05-23-2023
By sperokesalga sperokesalga • 02-21-2023
By PurpleRose PurpleRose • 07-26-2022
By Marketwired • 08-03-2023
By Value_Insider Value_Insider • 10-25-2022
By sperokesalga sperokesalga • 04-17-2023
By Stock market mentor Stock market mentor • 02-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.